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Abstract
Induction of fetal hemoglobin (HbF) has therapeutic importance for patients with sickle cell disease (SCD) and the beta-
thalassemias. It was recently reported that increased expression of LIN28 proteins or decreased expression of its target let-7
miRNAs enhances HbF levels in cultured primary human erythroblasts from adult healthy donors. Here LIN28A effects were
studied further using erythrocytes cultured from peripheral blood progenitor cells of pediatric subjects with SCD.
Transgenic expression of LIN28A was accomplished by lentiviral transduction in CD34(+) sickle cells cultivated ex vivo in
serum-free medium. LIN28A over-expression (LIN28A-OE) increased HbF, reduced beta (sickle)-globin, and strongly
suppressed all members of the let-7 family of miRNAs. LIN28A-OE did not affect erythroblast differentiation or prevent
enucleation, but it significantly reduced or ameliorated the sickling morphologies of the enucleated erythrocytes.
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Introduction
Sickle Cell Disease (SCD) and the beta-thalassemias are among
the most prevalent genetic disorders worldwide with high levels of
morbidity and mortality [1,2]. Our understanding of these beta-
hemoglobinopathies at both the clinical and molecular levels has
increased greatly in recent decades [3]. However, despite a
homogeneous genetic mutation, clinical outcomes and response to
therapy vary widely among patients with SCD [4].
Pharmaceutical induction of fetal hemoglobin (HbF) is an
effective approach toward therapy [1]. HbF levels of 20% or
greater are associated with improvements in the SCD patients’
clinical status [5]. Therefore, manipulation of HbF levels in
human erythrocytes remains an intense topic of benign hematol-
ogy research. As a result, significant knowledge regarding the
molecular mechanisms underlying HbF regulation has been
uncovered. For instance, gene linkage studies associated BCL11A,
HSB1L-MYB and HBB regions in the genome with increased
HbF expression in adults [6–9], and suppression of BCL11A
causes an increase in HbF levels and reverses the SCD phenotype
in model systems [10,11].
Recently, LIN28A and LIN28B proteins as well as let-7
microRNAs (miRNAs) were shown to cause a partial reversal of
ontogeny-related changes in the human erythroid phenotype
including increased expression of HbF in adult cells [12]. The
highly conserved RNA-binding LIN28 proteins are known to
control developmentally-timed events in multicellular organisms
by negatively regulating the biogenesis of let-7 miRNAs [13].
Human let-7 miRNAs demonstrate increased expression in adult
human reticulocytes when compared to cord blood reticulocytes
[14].
Here we study erythrocytes cultured from purified CD34(+) cells
from children with SCD to further explore the potential for
transgenic erythroid LIN28A expression to decrease let-7
miRNAs levels and increase HbF expression. We also report a
novel assay for exploring the effects of increased HbF expression
upon the sickling phenomenon using purified erythrocytes
generated in serum-free culture.
Methods
Ethics Statement
Institutional Review Board approval for the study and the
informed consent process was obtained from Children’s National
Medical Center and the National Institute of Diabetes and
Digestive and Kidney Diseases. Written informed consent was
obtained from the parent or legal guardian for all research
participants less than 18 years of age and from all research subjects
18 years of age or older prior to participation in this study. Written
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assent was obtained from all participants between the ages of 7 and
17 years of age.
Patients and samples
Discarded whole blood from partial manual exchange transfu-
sions was collected from five pediatric research subjects with HbSS
genotype (ages 9–16 years) who were at steady state and not being
treated with hydroxyurea. The partial manual exchange transfu-
sions were performed as primary (Donors 1–4) or secondary
(Donor 5) stroke prophylaxis every 4 to 5 weeks. The chronic
transfusion regimens had been in place for a range of 3 to 11 years
at the time of this study. Patient’s clinical features are described in
Table 1. After the RBCs were lysed (ACK Lysing Buffer, Lonza,
Walkersville, MD), CD34(+) cells were isolated using CD34
antibodies conjugated to magnetic microbeads (CliniMACS CD34
Reagent, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)
and a magnetic column (CliniMACS Instrument, Miltenyi Biotec).
Cell culture
Ex vivo culture was performed in a 3-week serum-free system
consisting of three phases (phase I from day 0 to 7, phase II from
day 7 to 14 and phase III from day 14 to 21) as previously

























































































































































































Figure 1. LIN28A over-expression in human sickle erythroblasts
was confirmed by (A) Q-RT-PCR quantitation of copy number
per nanogram of complementary DNA (cDNA) (copies/ng
cDNA) and (B) Western blot analysis. Analyses were performed
at culture day 14. Open bars represent control and black bars represent
LIN28A over-expression. C: empty vector control; OE: LIN28A over-
expression.
doi:10.1371/journal.pone.0106924.g001
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Recombinant viral transduction
Human LIN28A over-expression and empty vector control
lentiviral particles were purchased from Qiagen (Valencia, CA).
On culture day 3 of phase I, CD34(+) cells were transduced with
LIN28A viral particles (estimated MOI 12). After 24 hours,
puromycin (Sigma Aldrich, St. Louis, MO) was added to the
culture. On culture day 7, cells were transferred to phase II
medium containing EPO and puromycin until culture day 9. After
culture day 9, cells were cultivated at the conditions previously
described without puromycin.
Flow cytometry analyses
On days 14 and 21, erythroid differentiation was assessed with
antibodies directed against CD71 and glycophorin A (Invitrogen,
Carlsbad, CA) using the BD FACSAria I flow cytometer (BD
Biosciences, San Jose, CA) as previously described [15]. Enucle-
ation was quantitated by thiazole orange (TO) staining (Sigma) on
day 21. Enucleated sickle erythrocytes [TO(2) population] were
sorted and imaged as described below. Flow cytometric analyses of
HbF were performed in cells fixed with paraformaldehyde and
stained with antibody against HbF as previously reported [16].
Quantitative PCR and Western analyses
Q-RT-PCR assays and Western analyses were performed as
previously described [12,14,17].
HPLC for sickle and fetal hemoglobins
Samples for HPLC analysis were prepared and analyzed as
previously described [15].
Low oxygen exposure and assessment of cellular
morphologies
Cells were cultured in a 3-week serum-free system as previously
described [12]. During the final week in culture, cells were
incubated in a 2% oxygen environment consistent with the lower
oxygen range estimated for human bone marrow [18]. Initial
experiments using cells from healthy volunteers demonstrated that
2% oxygen conditions significantly increased enucleation com-
pared to matched cells cultured in a 21% environment (21%
oxygen: 29.5610.5%; 2% oxygen: 44.0613.9%; p = 0.019; Figure
S1). Enucleated cells detected by thiazole orange staining were
sorted directly into wells containing culture medium [duplicate
plates for control and LIN28A over-expression (LIN28A-OE)
transductions]. Sorted cells as well as control erythrocytes from
individuals with HbSS were incubated for 16 hours at 2% oxygen
prior to imaging studies. All images were taken within three
minutes after removal from 2% oxygen without further manipu-
lation of the cells. Cell imaging was accomplished using an
Figure 2. LIN28A over-expression strongly suppresses all
members of the let-7 family of miRNAs in cultured human
sickle erythroblasts. (A) LIN28A over-expression compared to control
samples in the relative expression levels of the let-7 family of miRNAs.
The miRNA relative expression levels (y-axis) in the control cells were
defined as a level of one for comparison. LIN28A over-expression
compared to control samples in the mRNA expression levels of (B)
BCL11A, (C) KLF1 and (D) SOX6. Analyses were performed at culture day
14. Open bars represent control and black bars represent LIN28A over-
expression. Mean value 6 SD of five independent research subjects for
each condition. P values were calculated using Student’s t-test. C:
empty vector control; OE: LIN28A over-expression. *p,0.05.
doi:10.1371/journal.pone.0106924.g002
Figure 3. LIN28A regulates gamma-globin mRNA levels in
cultured human sickle erythroblasts. LIN28A over-expression
compared to control samples in the mRNA expression levels of (A)
alpha-, mu-, theta- and zeta-globins and (B) beta-, delta-, gamma- and
epsilon-globins. Analyses were performed at culture day 14. Open bars
represent control and black bars represent LIN28A over-expression.
Mean value 6 SD of five independent research subjects for each
condition. P values were calculated using Student’s t-test. *p,0.05.
doi:10.1371/journal.pone.0106924.g003
LIN28A Expression Reduces Sickling
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inverted microscope (32X magnification) equipped with a Zeiss
AxioCam MRc5 camera (Carl Zeiss, Oberkochen, Germany).
Four random fields were imaged from each well, and cellular
morphologies were scored by blinded observers.
Statistical analysis
Mean 6 SD values were used for calculating statistical
significance by Student’s t-test.
Results
LIN28A suppresses the let-7 family of miRNAs in human
CD34(+) sickle cells
Increased LIN28 in cultured erythroblasts from adult healthy
donors causes increased gamma-globin gene and protein expres-
sion as they differentiate in culture [12]. As a result, the HbF
content of the enucleated erythrocytes that are produced is also
elevated. To explore these effects in primary sickle cells, we
investigated LIN28A-OE using erythroblasts from five children
with SCD. CD34(+) cells were transduced with a LIN28A
encoding lentivirus, and LIN28A-OE was confirmed by Q-RT-
PCR (control: 8.6E+0068.1E+00 copies/ng, LIN28A-OE: 2.3E+
0562.1E+05 copies/ng, p = 0.033) and Western blot analyses
(Figure 1). LIN28A-OE did not affect the expression of its
homolog LIN28B as assessed by Q-RT-PCR on culture day 14
(data not shown). As expected, LIN28A-OE strongly suppressed
the levels of all let-7 miRNA family members, with average
reductions from 64–96% for let-7a, let-7b, let-7c, let-7d, let-7e, let-
7f-2, let-7g, let-7i and miR-98 (Figure 2A). LIN28A-OE medi-
ated changes in the expression of BCL11A, KLF1 and SOX6,
erythroid transcription factors involved in the regulation of HbF
[10,19], were not statistically significant (Figure 2B–D). Examina-
tion of BCL11A expression in each donor’s cells revealed variable
changes associated with LIN28A-OE when compared with
controls (Figure S2).
LIN28A regulates fetal hemoglobin expression but does
not affect erythroid differentiation or enucleation of
cultured sickle erythrocytes
Expression of the globin genes demonstrated no major
differences in alpha-, mu-, theta-, zeta-, delta- and epsilon-globins
mRNA levels among LIN28A-OE cells (Figure 3A). However,
gamma-globin mRNA expression levels increased significantly in
LIN28A-OE samples (control: 2.0E+0667.0E+05 copies/ng,
LIN28A-OE: 1.5E+0766.0E+06 copies/ng, p = 0.006), and beta
(sickle)-globin mRNA decreased in LIN28A-OE samples (control:
2.0E+0765.2E+06 copies/ng, LIN28A-OE: 1.6E+0766.3E+
06 copies/ng, p = 0.024; Figure 3B).
Consistent with the changes in mRNA levels, LIN28A-OE
increased the percentage of HbF compared to controls. Increased
HbF was detected by HPLC for each donor (Figure 4A–J). The
mean increase in HbF was statistically significant (control:
10.867.1%, range 2.3 to 22%; LIN28A-OE: 40.1614.0%, range
17.6 to 51.2%; p = 0.003). The absence of HbA or other major
peaks confirmed the HbSS phenotype. Fetal hemoglobin staining
demonstrated a pancellular shift in HbF staining when compared
to the isotypic controls (Figure S3). A bimodal distribution of HbF-
mediated fluorescence intensity was noted in the controls. By
comparison, LIN28A-OE caused a significant increase of cells
demonstrating higher level fluorescence (control: 45.0617.6%,
LIN28A-OE: 66.5618.6%, p = 0.007).
According to flow cytometry analyses of transferrin receptor
(CD71) and glycophorin A (GPA), erythroblast differentiation was
not affected by LIN28A-OE (Figure S4A). Furthermore, thiazole
orange (TO) staining, showed equivalent enucleation achieved
between the LIN28A-OE cells and the control transductions at
culture day 21 (LIN28A-OE enucleation 40.8617.0% compared
to control 49.9623.4%, p = 0.19; Figure S4B). Upon completion
of the culture period (day 21), cell counts in LIN28A-OE and
control transductions were equivalent (data not shown). Taken
together, these data show that transgenic expression of LIN28A in
erythroblasts from pediatric subjects with sickle cell anemia
Figure 4. LIN28A regulates fetal hemoglobin levels in cultured
human sickle erythroblasts. HPLC analysis of hemoglobin from
control and LIN28A-OE samples were performed at culture day 21.
Donor 1 (A) Control and (B) LIN28A-OE, Donor 2 (C) Control and (D)
LIN28A-OE, Donor 3 (E) Control and (F) LIN28A-OE, Donor 4 (G) Control
and (H) LIN28A-OE and Donor 5 (I) Control and (J) LIN28A-OE. HbF and
HbS peaks are labeled with the ratio of HbF/HbF+HbS expressed as a
percentage above each HbF peak (y-axis, mVolts; x-axis, elution time in
minutes).
doi:10.1371/journal.pone.0106924.g004
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regulates both fetal and beta (sickle)-globin expression with
comparable ex vivo differentiation of the cells.
LIN28A reduces hypoxia-related sickling
Based upon the demonstration of robust enucleation, we next
determined whether sickle cell morphologies could be identified
among the cultured erythroblasts. The assay was developed using
cells from the first three donors, and the morphologies were scored
for comparison using Donor 4 and Donor 5 cells. Microscopic
examination showed morphologies that were characteristically
similar to those reported from human blood including elongated,
maple-leaf, and the classic ‘‘sickle’’ shaped cells [20] (See Figure 5
and Figure S5). By comparison, images from healthy HbAA donor
cells produced round morphologies in culture (Figure S6). As a
result of these differences, the cellular populations were scored
according to two general categories: round cells (no evidence of
sickle morphology) versus cells with non-round shapes defined in
this study as possessing variable sickle morphologies. Further
attempts to subcategorize were not made due to the broad range of
abnormal morphologies. According to this scoring method, control
erythrocytes obtained from HbSS donors’ peripheral blood that
were maintained under the same 2% oxygen environment in
culture medium demonstrated sickled morphologies in 88.865.4%
of the cells.
The same morphology scoring method (round versus non-
round) was utilized to quantitate LIN28A-OE effects upon the
morphological sickling phenomenon. Images from the control and
LIN28A-OE transductions were assigned random numbers, and
then scored by blinded observers. Cellular debris or non-
hemoglobinized cellular ghosts (less than 10% of particles) were
not scored. The percentages of cells from each donor that
demonstrated variable sickled morphologies (non-round) were
compared between LIN28A-OE and control transductions.
Representative fields are shown in Figure 5A–D (all microscopic
fields are shown in Figure S5). LIN28A-OE caused significant
reductions in the variable sickle morphologies in both donors’
cells. In Donor 4, LIN28A-OE caused HbF expression to increase
in the cells to 51.2% (versus control HbF 9.9%), with a marked
reduction in the variable sickle morphologies of the cultured
erythrocytes (control: 7967.8%, LIN28A-OE: 41.6611.1%,
p = 0.00004; Figure 5E). In Donor 5 cells, LIN28A-OE caused
increased HbF levels to 17.6% (versus control HbF 2.3%), and
caused a less intense reduction in the variable sickle morphologies
(control: 94.162.3%, LIN28A-OE: 81.864.4%, p = 0.0003;
Figure 5F). While both donors demonstrated decreases in sickling,
Figure 5. LIN28A over-expression ameliorates abnormal morphologies associated with sickle mature erythrocytes. Cell images are
representative from two independent research subjects as follows: Donor 4 (A) control and (C) LIN28A-OE, and Donor 5 (B) control and (D) LIN28A-
OE. Cells were scored according to round versus variable sickle morphologies (non-round). Average cell counts of variable sickle morphologies from
Donor 4 (E) and Donor 5 (F). Error bars denote 6 SD of 8 fields for each condition per donor. P values were calculated using Student’s t-test. Control:
empty vector control; LIN28A-OE: LIN28A over-expression. *p,0.05.
doi:10.1371/journal.pone.0106924.g005
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PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e106924
the more robust reduction in Donor 4 cells occurred in association
with the greater increase in HbF.
Discussion
The lin28 gene was first described in the nematode Caenor-
habditis elegans as a heterochronic gene that regulates timing and
sequence of developmental events [21]. Two homologs of the
lin28 gene – LIN28A and LIN28B – have been identified in
humans and were correlated with the pluripotency of stem cells
[22], differentiation of skeletal muscle cells [23], and developmen-
tal timing characteristics such as variation in height [24], timing of
puberty [25,26] and age at natural menopause [26]. LIN28 genes
are known to regulate the let-7 family of miRNAs, and the
expression of LIN28 transcripts is associated with the inhibition of
let-7 [13]. The LIN28-let-7 axis is highly conserved across
evolution, serving as a regulator of cell growth and development in
a cellular/tissue specific manner. In erythroid biology, the let-7
family of miRNAs was associated with the developmental
transition from fetal to adult erythropoiesis, since several members
of the let-7 family are up-regulated in adult compared to cord
blood human reticulocytes samples [14]. Recently, expression of
either LIN28 protein in adult erythroblasts caused reductions in
let-7 miRNAs as well as increases in HbF expression [12]. Here
our studies with LIN28A over-expression demonstrate similar
effects in cultured human sickle cells. LIN28A-OE was also shown
to reduce the cell-sickling phenomenon in these cultured cells.
Potential effects of LIN28A-OE upon the expression of
BCL11A, SOX6 and KLF1 were also studied [12,27]. BCL11A
was previously associated with the human genetic variation in HbF
levels [6,7,9,24], the regulation of HbF in adult erythroid cells
[10], and the amelioration of the SCD phenotype in adult mice
models of the disease [11]. In SCD patients, BCL11A has been
associated with the baseline levels of fetal hemoglobin [28] and
was down-regulated by hydroxyurea treatment in early reticulo-
cytes [29]. In cooperation with BCL11A, the transcription factor
SOX6 was also reported to occupy the human beta-globin cluster
and play a role in regulating HbF in adult human erythroid cells
[30]. KLF1 was identified as a regulator of BCL11A expression in
human erythroid cells [19]. Significant reductions in BCL11A
expression upon the transgenic over-expression of LIN28 were
previously detected in cells from healthy donors [12]. In this study,
the suppression of BCL11A expression was not consistent among
the 5 donors (Figure S2), and LIN28A over-expression with let-7
miRNAs suppression did not significantly change the mean
expression levels of BCL11A, KLF1 or SOX6 (Figure 2B–D).
Further, all the samples demonstrated increased levels of HbF, but
those increases were not well correlated with the levels of LIN28A
over-expression (compare Figures 1 and 4). These results empha-
size the current lack of mechanistic understanding for how
LIN28/let-7 mediates increases in HbF expression. Future studies
of LIN28A, including examination of alternate model systems and
determination of the minimal LIN28A levels required for its
regulation of globin gene expression, are needed.
The sickling morphology of erythrocytes is due to polymeriza-
tion of hemoglobin S with formation of intracellular fibers [31].
For decades, a combination of basic and clinical research has been
aimed toward augmentation of HbF because of its sparing effects
on sickle hemoglobin polymerization [5,32]. We developed a novel
approach for studies of the sickling phenomenon using culture-
generated erythrocytes. During the terminal stages of differenti-
ation, the erythroblasts were cultured in a 2% oxygen environment
consistent with levels in bone marrow [17,33]. Highly purified
populations of enucleated cells were then imaged to demonstrate
sickle morphologies. LIN28A-OE significantly reduced the
morphological sickling in both donors’ cells. While several factors
are involved in the cellular sickling phenomenon [34,35],
increased HbF expression in LIN28A-OE cells is thought to play
a critical role in reducing the morphological abnormalities.
In summary, LIN28A-OE reduced let-7 miRNAs levels and
increased HbF expression in erythroblasts cultured from CD34(+)
cells from pediatric sickle cell anemia donors’ blood at magnitudes
similar to those previously reported using cells from healthy adults.
The ex vivo culture model was explored in the context of tissue
engineering to demonstrate reduction of the sickling phenomenon
among the enucleated cells. As such, these data support further
studies of the LIN28/let-7 regulatory axis in erythroid biology
with the eventual goal of identifying new therapeutic interventions
for beta-hemoglobinopathies.
Supporting Information
Figure S1 Low oxygen culture conditions (2% oxygen)
compared to 21% oxygen culture conditions increases
erythroid enucleation of cultured CD34+ cells from
healthy volunteers. Enucleation was assessed by thiazole
orange staining. Flow cytometry analyses of three independent
healthy volunteers were performed at culture day 21. HV =
healthy volunteer.
(TIF)
Figure S2 Effect of LIN28A over-expression upon the
expression levels of BCL11A. BCL11A mRNA levels were
investigated by Q-RT-PCR quantitation of copy number
per nanogram of complementary DNA (cDNA) (copies/
ng cDNA) at culture day 14. Open bars represent control and
black bars represent LIN28A over-expression. C: empty vector
control; OE: LIN28A over-expression.
(TIF)
Figure S3 LIN28A over-expression increases the per-
centage of cells with high-levels of fetal hemoglobin. Fetal
hemoglobin staining was assessed by flow cytometry analysis of
control and LIN28A-OE samples on culture day 21. Cell analyses
from (A) Donor 1, (B) Donor 2, (C) Donor 3, (D) Donor 4 and
(E) Donor 5 are shown. Fluorescence units (FU) for cells stained
with the isotypic control antibody (IgG1) are shown in the shaded
histograms. Fluorescence from the anti-HbF stained, control and
LIN28A-OE transduced cells are demonstrated by dotted- and
bold-lined histograms, respectively. The bar in the upper right of
each panel denotes the fluorescence within the upper two decades
(defined here and described in the text as high-level fluorescence).
(TIF)
Figure S4 LIN28A over-expression in human sickle
erythroblasts does not affect erythroblast differentiation
and enucleation. Flow cytometry analyses of (A) control and
LIN28A-OE at culture day 14 and day 21 stained with anti-
transferrin receptor (CD71) and anti-glycophorin A (GPA)
antibodies. (B) Enucleation was assessed by thiazole orange
staining of culture day 21 for control and LIN28A-OE cells. Data
are representative of five independent research subjects. Control:
empty vector control; LIN28A-OE: LIN28A over-expression.
(TIF)
Figure S5 Microscopic fields of HbSS cells. Enucleated
cells from Donor 4 (A) control and (B) LIN28A-OE, and
Donor 5 (C) control and (D) LIN28A-OE. The square in the
LIN28A Expression Reduces Sickling
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e106924
first field from each image corresponds to the representative field
shown in Figure 5. Control: empty vector control; LIN28A-OE:
LIN28A over-expression.
(TIF)
Figure S6 Enucleated erythroid cells from healthy
HbAA donor. Representative fields from (A) control (non-
transduced cells) and (B) transduced cells. Culture conditions, cell
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